TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today gastroenterology roundup published Oct. 22, 2026, highlighted joint AGA and AASLD guidelines for primary biliary cholangitis and UEG Week research associating antibiotic use in childhood and young adulthood with higher odds of IBS. The roundup also covered liver transplant preparation research, investigational treatments, and consumer constipation tips; it does not provide the full guideline recommendations or study data.
A gastroenterology roundup published Oct. 22 reported that the American Gastroenterological Association (AGA) and American Association for the Study of Liver Diseases (AASLD) have issued joint guidelines on primary biliary cholangitis, while research presented at United European Gastroenterology Week associated antibiotic use in childhood and young adulthood with higher odds of irritable bowel syndrome (IBS). The report flags several developments but does not provide the full guideline recommendations or detailed study results.
The guidelines, published in the journal Hepatology, address management of primary biliary cholangitis, a chronic liver disease. The roundup identifies the two organizations behind the guidance but does not summarize its specific recommendations, intended patient groups, or how it differs from earlier advice. Readers seeking treatment decisions would need the guideline itself and advice from their clinicians.
Separately, research presented at UEG Week linked antibiotic use during childhood and young adulthood with increased odds of IBS. The report does not give the study design, number of participants, types or duration of antibiotic exposure, or the size of the association. The finding is an association as described in the roundup; it does not establish that antibiotics caused IBS.
Other items in the roundup included research suggesting that an individualized program of exercise and dietary changes before liver transplantation may improve candidates’ chances of surviving long enough to receive an organ. It also noted phase II drug-development reports: Gilead Sciences reported data for investigational emvistegrast in ulcerative colitis, and AbbVie reported a trial of ABBV-466 in Crohn’s disease. These are early-stage developments, not evidence of approved treatments.
Guidance and Evidence for Digestive Care
The joint PBC guidance is relevant to clinicians caring for people with a chronic liver condition because it offers a shared professional reference from two major US medical organizations. The supplied report does not detail the recommendations, so it cannot support conclusions about specific treatment changes or expected patient outcomes.
The antibiotic-IBS finding may prompt further attention to how exposure to antibiotics early in life relates to digestive health. But without study details or evidence of causation, it should not be read as a reason to avoid antibiotics when medically indicated. Prescribing decisions depend on a patient’s circumstances and a qualified clinician’s judgment.
The transplant and drug-trial reports also sit at different stages of evidence. A possible benefit from prehabilitation and results from phase II trials can guide further research, but neither is presented in the roundup as definitive proof of benefit or as a new standard of care.
constipation cookies dietary supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Three Strands of Gastroenterology News
The source is a short MedPage Today news-and-commentary roundup by Managing Editor Ian Ingram, dated Oct. 22, 2026. It combines clinical research, professional guidance, drug-development announcements, and links to consumer-facing coverage rather than reporting one single study in depth.
Alongside the PBC guidelines and IBS association, the roundup referenced a scoping review that supported consideration of population screening for celiac disease, an update of treatment targets in inflammatory bowel disease, and research on liver disease screening during colonoscopy. It also mentioned a halted hepatitis B vaccine trial in Guinea-Bissau, attributing the information to the trial’s lead researcher as reported by The Guardian. These items are separate developments and should not be treated as findings from one coordinated study.
Consumer coverage cited in the roundup included a gastroenterologist’s fiber-focused “constipation cookies” recipe and a discussion of whether blowing bubbles while using the toilet could help with constipation. The roundup provides no clinical trial evidence for either approach.
“Antibiotic use in childhood and young adulthood was linked to increased odds of irritable bowel syndrome.”
— MedPage Today roundup, citing research presented at UEG Week
Study Details Still Missing
The supplied report does not state the specific recommendations in the PBC guideline, when they take effect, or whether the organizations recommend changes from prior practice. It also omits the antibiotic study’s design, participant numbers, exposure definitions, statistical estimates, and whether researchers adjusted for other factors that might affect IBS risk.
The transplant prehabilitation report is described as suggesting a possible benefit, but the roundup does not give enough information to assess the size or reliability of that effect. The phase II drug reports are likewise summarized without full trial results, adverse-event data, or details needed to compare them with existing care. No approval or guideline adoption is reported for these investigational therapies.
For the consumer constipation items, the source provides links and brief descriptions rather than evidence evaluating the approaches. The roundup also does not establish a connection between the separate developments it lists.
Full Guidance and Trial Results
The next useful step for readers is to consult the full PBC guideline in Hepatology for its recommendations and supporting evidence. More detailed publication of the UEG Week IBS research would be needed to assess the association, including the study methods and numerical results.
Further reporting or peer-reviewed results could clarify whether prehabilitation changes transplant outcomes and how the investigational ulcerative colitis and Crohn’s disease therapies perform in larger or later-stage trials. The roundup itself does not give dates for those developments, so their timing remains unknown.
Key Questions
What did the new primary biliary cholangitis guidelines do?
The AGA and AASLD published joint management guidelines in Hepatology. The roundup confirms their publication but does not list the recommendations.
Do antibiotics cause IBS, according to the report?
No causal conclusion is provided. Research presented at UEG Week linked earlier-life antibiotic use with increased odds of IBS, but the roundup gives no study details that would establish cause and effect.
What does the transplant prehabilitation finding suggest?
The report says an individualized program combining exercise and dietary changes may help candidates survive until they receive a liver. It does not provide the size of the potential benefit or enough details to judge the evidence.
Are the reported IBD drugs approved treatments?
The roundup describes phase II trial findings for investigational therapies. It does not report regulatory approval, and early-stage trial results do not establish that a drug is an approved standard treatment.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
